Search

Your search keyword '"Borthakur, Gautham"' showing total 23 results
Start Over Author "Borthakur, Gautham"
23 results on '"Borthakur, Gautham"'

1. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Author

Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Takahashi, Koichi, Jabbour, Elias, Borthakur, Gautham, Pemmaraju, Naveen, Konopleva, Marina, Soltysiak, Kelly A., Pierce, Sherry R., Bueso-Ramos, Carlos E., Patel, Keyur P., Kantarjian, Hagop, and Garcia-Manero, Guillermo

Published
2020
Full Text
View/download PDF

2. Augmented Berlin‐Frankfurt‐Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)

Author

Rytting, Michael E, Thomas, Deborah A, O'Brien, Susan M, Ravandi‐Kashani, Farhad, Jabbour, Elias J, Franklin, Anna R, Kadia, Tapan M, Pemmaraju, Naveen, Daver, Naval G, Ferrajoli, Alessandra, Garcia‐Manero, Guillermo, Konopleva, Marina Y, Cortes, Jorge E, Borthakur, Gautham, Garris, Rebecca, Cardenas‐Turanzas, Maria, Schroeder, Kurt, Jorgensen, Jeffrey L, Kornblau, Steven M, and Kantarjian, Hagop M

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Oncology and Carcinogenesis, Childhood Leukemia, Stem Cell Research, Pediatric Cancer, Pediatric Research Initiative, Pediatric, Orphan Drug, Rare Diseases, Cancer, Hematology, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, Asparaginase, Cohort Studies, Consolidation Chemotherapy, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone, Doxorubicin, Female, Humans, Induction Chemotherapy, Maintenance Chemotherapy, Male, Mercaptopurine, Methotrexate, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Prospective Studies, Thioguanine, Treatment Outcome, Vincristine, Young Adult, Philadelphia chromosome-negative ALL, acute lymphoblastic leukemia, augmented Berlin-Frankfurt-Münster, pediatric-based regimens, pediatric-based therapy, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis, Public health
Abstract

BackgroundVarious trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Münster (ABFM) regimen in AYA patients. The results were compared with those from a similar population that received the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen.MethodsEighty-five patients ages 12 to 40 years who had Philadelphia chromosome (Ph)-negative ALL received the ABFM regimen from October 2006 through April 2012. Their outcome was compared with outcomes in 71 historic AYA patients who received hyper-CVAD from the authors' institution. Patient and disease characteristics, as well as minimal residual disease status, were analyzed for their impact on outcomes.ResultsThe complete response rate with ABFM was 94%. The 3-year complete remission duration (CRD) and overall survival (OS) rates were 70% and 74%, respectively. For patients aged ≤21 years, the 3-year CRD and OS rates were 72% and 85%, respectively; and, for patients ages 21 to 40 years, the respective rates were 69% and 60%. The initial white blood cell count was an independent predictive factor of OS and CRD. The minimal residual disease status on days 29 and 84 of therapy also were predictive of long-term outcomes. Severe regimen toxicities included transient hepatotoxicity in 35% to 39% of patients, pancreatitis in 11% of patients, osteonecrosis in 11% of patients, and thrombosis in 22% of patients. The 3-year OS rate was 74% in the ABFM group versus 71% in the hyper-CVAD group, and the corresponding 3-year CRD rate was 70% versus 66%, respectively.ConclusionsABFM was tolerable in AYA patients with ALL but was not associated with significant improvements in CRD and OS compared with hyper-CVAD.

Published
2014

3. MDS-614 Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations

Author

Kontoyiannis, Panayiotis, primary, Peddireddy, Arjun, additional, Sasaki, Koji, additional, Chien, Kelly, additional, Montalban-Bravo, Guillermo, additional, DiNardo, Courtney, additional, Borthakur, Gautham, additional, Kanagal-Shamanna, Rashmi, additional, Bueso-Ramos, Carlos, additional, Pierce, Sherry, additional, Kantarjian, Hagop, additional, Garcia-Manero, Guillermo, additional, and Urrutia, Samuel, additional

Published
2023
Full Text
View/download PDF

4. POSTER: MDS-614 Causes of Death in Patients With Myelodysplastic Syndrome and Spliceosome Mutations

Author

Kontoyiannis, Panayiotis, primary, Peddireddy, Arjun, additional, Sasaki, Koji, additional, Chien, Kelly, additional, Montalban-Bravo, Guillermo, additional, DiNardo, Courtney, additional, Borthakur, Gautham, additional, Kanagal-Shamanna, Rashmi, additional, Bueso-Ramos, Carlos, additional, Pierce, Sherry, additional, Kantarjian, Hagop, additional, Garcia-Manero, Guillermo, additional, and Urrutia, Samuel, additional

Published
2023
Full Text
View/download PDF

5. Incidence of Central Nervous System Toxicity and Cytokine Release Syndrome in Leukemia Patients Treated with Blinatumomab

Author

Jabbour, Elias, primary, Paul, Shilpa, additional, Nichols, Dan E., additional, Darbaniyan, Faezeh, additional, Lee, Jenessa, additional, Sasaki, Koji, additional, Short, Nicholas, additional, Jain, Nitin, additional, Ravandi, Farhad, additional, Garcia-Manero, Guillermo, additional, Kadia, Tapan M., additional, Montalban-Bravo, Guillermo, additional, Borthakur, Gautham, additional, Garris, Rebecca, additional, Konopleva, Marina, additional, and Kantarjian, Hagop, additional

Published
2022
Full Text
View/download PDF

9. Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study

Author

Schimmer, Aaron D., Herr, Wolfgang, Hänel, Mathias, Borthakur, Gautham, Frankel, Arthur, Horst, Heinz-August, Martin, Sonja, Kassis, Jeannine, Desjardins, Pierre, Seiter, Karen, Fiedler, Walter, Noppeney, Richard, Giagounidis, Aristoteles, Jacob, Christine, Jolivet, Jacques, Tallman, Martin S., and Koschmieder, Steffen

Published
2011
Full Text
View/download PDF

12. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Author

Rivera, Daniel, primary, Kadia, Tapan M., additional, Montalban-Bravo, Guillermo, additional, Faderl, Stefan, additional, Sasaki, Koji, additional, Short, Nicholas J., additional, Daver, Naval, additional, DiNardo, Courtney D., additional, Masarova, Lucia, additional, Ferrajoli, Alessandra, additional, Jabbour, Elias J., additional, Borthakur, Gautham, additional, Al Azzawi, Hind, additional, Konopleva, Marina, additional, Garcia-Manero, Guillermo, additional, Andreeff, Michael, additional, Kantarjian, Hagop, additional, Ravandi, Farhad, additional, and Alvarado, Yesid, additional

Published
2021
Full Text
View/download PDF

13. Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Author

Ramos Perez, Jorge M., Kadia, Tapan M., Montalban-Bravo, Guillermo, Faderl, Stefan, Sasaki, Koji, Daver, Naval, DiNardo, Courtney D., Masarova, Lucia, Ferrajoli, Alessandra, Jabbour, Elias, Borthakur, Gautham, Al Azzawi, Hind, Pemmaraju, Naveen, Konopleva, Marina, Pierce, Sherry A., Garcia-Manero, Guillermo, Andreeff, Michael, Kantarjian, Hagop M., Ravandi, Farhad, and Alvarado, Yesid

Published
2020
Full Text
View/download PDF

14. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Author

Montalban-Bravo, Guillermo, primary, Kanagal-Shamanna, Rashmi, additional, Sasaki, Koji, additional, Patel, Keyur, additional, Ganan-Gomez, Irene, additional, Jabbour, Elias, additional, Kadia, Tapan, additional, Ravandi, Farhad, additional, DiNardo, Courtney, additional, Borthakur, Gautham, additional, Takahashi, Koichi, additional, Konopleva, Marina, additional, Komrokji, Rami S., additional, DeZern, Amy, additional, Kuzmanovic, Teodora, additional, Maciejewski, Jaroslaw, additional, Pierce, Sherry, additional, Colla, Simona, additional, Sekeres, Mikkael A., additional, Kantarjian, Hagop, additional, Bueso-Ramos, Carlos, additional, and Garcia-Manero, Guillermo, additional

Published
2019
Full Text
View/download PDF

15. Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Author

Montalban-Bravo, Guillermo, primary, Takahashi, Koichi, additional, Patel, Keyur, additional, Wang, Feng, additional, Xingzhi, Song, additional, Nogueras, Graciela M., additional, Huang, Xuelin, additional, Pierola, Ana Alfonso, additional, Jabbour, Elias, additional, Colla, Simona, additional, Gañan-Gomez, Irene, additional, Borthakur, Gautham, additional, Daver, Naval, additional, Estrov, Zeev, additional, Kadia, Tapan, additional, Pemmaraju, Naveen, additional, Ravandi, Farhad, additional, Bueso-Ramos, Carlos, additional, Chamseddine, Ali, additional, Konopleva, Marina, additional, Zhang, Jianhua, additional, Kantarjian, Hagop, additional, Futreal, Andrew, additional, and Garcia-Manero, Guillermo, additional

Published
2018
Full Text
View/download PDF

16. Genomic context and TP53allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Author

Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad, Daver, Naval, Takahashi, Koichi, Jabbour, Elias, Borthakur, Gautham, Pemmaraju, Naveen, Konopleva, Marina, Soltysiak, Kelly A., Pierce, Sherry R., Bueso-Ramos, Carlos E., Patel, Keyur P., Kantarjian, Hagop, and Garcia-Manero, Guillermo

Abstract

TP53mutations are associated with adverse outcomes and shorter response to hypomethylating agents (HMAs) in myelodysplastic syndrome (MDS). Limited data have evaluated the impact of the type, number, and patterns of TP53mutations in response outcomes and prognosis of MDS. We evaluated the clinicopathologic characteristics, outcomes, and response to therapy of 261 patients with MDS and TP53mutations. Median age was 68 years (range, 18-80 years). A total of 217 patients (83%) had a complex karyotype. TP53mutations were detected at a median variant allele frequency (VAF) of 0.39 (range, 0.01-0.94). TP53deletion was associated with lower overall response rate (ORR) (odds ratio, 0.3; P= .021), and lower TP53VAF correlated with higher ORR to HMAs. Increase in TP53VAF at the time of transformation was observed in 13 patients (61%), and previously undetectable mutations were observed in 15 patients (65%). TP53VAF was associated with worse prognosis (hazard ratio, 1.02 per 1% VAF increase; 95% confidence interval, 1.01-1.03; P< .001). Integration of TP53VAF and karyotypic complexity identified prognostic subgroups within TP53-mutant MDS. We developed a multivariable model for overall survival that included the revised International Prognostic Scoring System (IPSS-R) categories and TP53VAF. Total score for each patient was calculated as follows: VAF TP53+ 13 × IPSS-R blast score + 16 × IPSS-R cytogenetic score + 28 × IPSS-R hemoglobin score + 46 × IPSS-R platelet score. Use of this model identified 4 prognostic subgroups with median survival times of not reached, 42.2, 21.9, and 9.2 months. These data suggest that outcomes of patients with TP53-mutated MDS are heterogeneous and that transformation may be driven not only by TP53but also by other factors.

Published
2020
Full Text
View/download PDF

17. Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies

Author

Falchi, Lorenzo, primary, Vitale, Candida, additional, Ciccone, Maria, additional, Hinojosa, Christina, additional, Keating, Michael, additional, Pemmaraju, Naveen, additional, Wierda, William, additional, Borthakur, Gautham, additional, Burger, Jan, additional, and Ferrajoli, Alessandra, additional

Published
2016
Full Text
View/download PDF

18. NPM1mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy

Author

Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Sasaki, Koji, Patel, Keyur, Ganan-Gomez, Irene, Jabbour, Elias, Kadia, Tapan, Ravandi, Farhad, DiNardo, Courtney, Borthakur, Gautham, Takahashi, Koichi, Konopleva, Marina, Komrokji, Rami S., DeZern, Amy, Kuzmanovic, Teodora, Maciejewski, Jaroslaw, Pierce, Sherry, Colla, Simona, Sekeres, Mikkael A., Kantarjian, Hagop, Bueso-Ramos, Carlos, and Garcia-Manero, Guillermo

Abstract

Nucleophosmin (NPM1) mutations are common in acute myeloid leukemia and are associated with high remission rates and prolonged survival with intensive chemotherapy. NPM1mutations are rare in myelodysplastic syndromes (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN), and the clinical outcomes of these patients, when treated with intensive chemotherapy, are unknown. We retrospectively evaluated the clinicopathologic characteristics and the impact of therapy in 31 patients with MDS or MDS/MPN and NPM1mutations. Next-generation sequencing was performed at diagnosis in 22 patients. Median age was 62 years (range, 19-86). Twenty-four patients (77%) had normal karyotype, and all had multilineage dysplasia. Most patients could be classified as MDS with excess blasts (19/31, 61%). NPM1mutations were detected at a median allele frequency of 0.38 (range, 0.09-0.49). Mutation burden did not correlate with bone marrow blast frequency, and its clearance seemed to be associated with decreased morphologic dysplasia. Ten of the 31 patients (32%) received cytotoxic chemotherapy, 20 (65%) hypomethylating agents, and 1 (4%) lenalidomide. Sequential sequencing was available in 16 (52%) patients, and mutation burden correlated with disease status and response to therapy. Patients treated with chemotherapy had higher complete response rates (90% vs 28%, P= .004), longer median progression-free survival (not reached vs 7.5 months, P= .023), and overall survival (not reached vs 16 months, P= .047). Intensive chemotherapy and allogeneic stem cell transplantation (SCT) may be associated with improved clinical outcomes in patients with NPM1-mutated MDS or MDS/MPN who are candidates for this form of therapy.

Published
2019
Full Text
View/download PDF

19. Updated definition of cure in adult patients with non-APL acute myeloid leukemia

Author

Tamamyan, Gevorg, primary, Döhner, Konstanze, additional, Borthakur, Gautham, additional, Paschka, Peter, additional, Ravandi, Farhad, additional, Gaidzik, Verena I., additional, Cortes, Jorge, additional, Döhner, Hartmut, additional, Garcia-Manero, Guillermo, additional, Thol, Felicitas, additional, Jabbour, Elias, additional, Heuser, Michael, additional, Daver, Naval, additional, Pierce, Sherry, additional, Ohanian, Maro, additional, Kolomansky, Albert, additional, Todisco, Gabriele, additional, Peng, S. Andrew, additional, Konopleva, Marina, additional, Kantarjian, Hagop, additional, Ganser, Arnold, additional, Kadia, Tapan, additional, and Schlenk, Richard F., additional

Published
2015
Full Text
View/download PDF

20. Pretreatment FMS like Tyrosine kinase-3 Internal Tandem duplication (FLT3-ITD) Mutant Allele Burden Does Not Predict Response to the Combination of Sorafenib and Azacytidine in Patients with Relapsed or High Risk Elderly Untreated Acute Myeloid Leukemia

Author

George, Binsah, primary, Cortes, Jorge, additional, Cabrero, Monica, additional, Jain, Nitin, additional, Konopleva, Marina, additional, Andreeff, Michael, additional, Tapan, Kadia, additional, Pierce, Sherry, additional, Dellasala, Sara, additional, Borthakur, Gautham, additional, Jabbour, Elias, additional, Garcia-Manero, Guillermo, additional, Kantarjian, Hagop, additional, and Ravandi, Farhad, additional

Published
2015
Full Text
View/download PDF

21. 1076

Author

Cardenas-Turanzas, Marylou, primary, Malik, Imrana, additional, Ravandi, Farhad, additional, Borthakur, Gautham, additional, Cortes, Jorge, additional, Kantarjian, Hagop, additional, Price, Kristen, additional, and Nates, Joseph, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results